Pr Zangen - BrainsWay Member CoFounder
| BRSYF Stock | USD 8.53 0.00 0.00% |
Insider
Pr Zangen is Member CoFounder of BrainsWay
| Age | 53 |
| Phone | 972 2 582 4030 |
| Web | https://www.brainsway.com |
BrainsWay Management Efficiency
The company has return on total asset (ROA) of (0.0751) % which means that it has lost $0.0751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2021) %, meaning that it generated substantial loss on money invested by shareholders. BrainsWay's management efficiency ratios could be used to measure how well BrainsWay manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Willem Appelo | Koninklijke Philips NV | 60 | |
| Michael Pederson | Abbott Laboratories | 59 | |
| Andrew Pierce | Stryker | 50 | |
| Christopher Scoggins | Abbott Laboratories | 54 | |
| Andre Hartung | Siemens Healthineers AG | N/A | |
| Didier Deltort | Zimmer Biomet Holdings | 52 | |
| Indra Nooyi | Koninklijke Philips NV | 66 | |
| Feike Sijbesma | Koninklijke Philips NV | 62 | |
| Elisabeth Staudinger | Siemens Healthineers AG | 53 | |
| Lisa Earnhardt | Abbott Laboratories | 54 | |
| J Pierce | Stryker | 47 | |
| Michael Roman | Abbott Laboratories | 61 | |
| Jereme Sylvain | DexCom Inc | 44 | |
| MSc MD | Medtronic PLC | N/A | |
| M Fink | Stryker | 51 | |
| Christopher Calamari | Abbott Laboratories | 50 | |
| James Young | Abbott Laboratories | N/A | |
| Paul Flynn | DexCom Inc | 55 | |
| Sean Christensen | DexCom Inc | N/A | |
| Michel DVM | Siemens Healthineers AG | 62 | |
| John Ginascol | Abbott Laboratories | 62 | |
Management Performance
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0751 |
BrainsWay Leadership Team
Elected by the shareholders, the BrainsWay's board of directors comprises two types of representatives: BrainsWay inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BrainsWay. The board's role is to monitor BrainsWay's management team and ensure that shareholders' interests are well served. BrainsWay's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BrainsWay's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Menachem Esq, Gen VP | ||
| Christopher Jako, Pres CEO | ||
| Avner Hagai, Founder and President and Director | ||
| Christopher Boyer, VP Marketing | ||
| Hadar Levy, VP COO | ||
| Yiftach Roth, Founder, Chief Scientist and Director | ||
| Moria Ankri, VP RD | ||
| Aron Tendler, Chief Officer | ||
| Pr Zangen, Member CoFounder | ||
| Richard Areglado, VP CFO |
BrainsWay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BrainsWay a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0751 | |||
| Profit Margin | (0.37) % | |||
| Operating Margin | (0.29) % | |||
| Current Valuation | (24.98 M) | |||
| Shares Outstanding | 33.08 M | |||
| Shares Owned By Insiders | 19.83 % | |||
| Shares Owned By Institutions | 1.11 % | |||
| Price To Earning | (23.91) X | |||
| Price To Book | 0.61 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in BrainsWay Pink Sheet
When determining whether BrainsWay offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BrainsWay's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainsway Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainsway Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BrainsWay. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in BrainsWay Pink Sheet please use our How to Invest in BrainsWay guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.